Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short term Debt (2024 - 2025)

Arcutis Biotherapeutics has reported Short term Debt over the past 2 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Short term Debt at $1.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.0 million (changed N/A YoY), and the annual figure for FY2025 was $1.0 million, changed.
  • Short term Debt for Q4 2025 was $1.0 million at Arcutis Biotherapeutics, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Short term Debt for ARQT hit a ceiling of $99.5 million in Q3 2024 and a floor of $1.0 million in Q2 2025.